TrialThe Journal of antimicrobial chemotherapy2020
The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
Gholamali Eslami et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
64 papers cite itlatest 60 shown
this paperpooled ittrialcites it